IDS and Technogenetics Finalise Agreement over Autoimmune and Infectious Disease Automated Assays

IDS and Technogenetics leaders shaking hands as they finalise an agreement

Immunodiagnostic Systems Holdings plc (“IDS”), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has reached agreement with Technogenetics srl (“TGS”) to enable IDS to sell TGS’s range of assay kits under the IDS brand, on a global basis.

TGS is an innovative company that has been active for over 30 years in the areas of diagnostic research and biotechnology. Since December 2015, TGS is part of the KHB Group, headquartered in Shanghai, and is engaged in complex and ambitious challenges with the aim of offering the market increasingly efficient and advanced diagnostic solutions. KHB is listed on the Shenzhen Stock Exchange.

TGS produces a broad range of CE approved CLIA automated assay kits for use in the fields of autoimmune and infectious disease diagnostics, which have been developed for the IDS-iSYS Multi-Discipline Automated System. This agreement follows a more restricted arrangement where IDS sold a limited number of the TGS assays in a small number of European countries. The new agreement, which runs for an initial period of ten years, gives IDS the right, subject to obtaining the necessary regulatory approvals, to sell the kits under the IDS brand on a worldwide basis.

These two assay portfolios serve as excellent tools for diagnosing and therapeutic monitoring of Autoimmune Diseases and Infectious Diseases:

Autoimmune Diseases are caused by the body producing an immune response against its own tissue structure. Measuring the relevant autoantibody load in the patient sample aids the diagnostic and therapy monitoring of these diseases. With these novel assays, diseases like the Mixed Connective Tissue Disease (e.g. Systemic Lupus Erythematosus), Rheumatoid Arthritis, Celiac Disease and Phospholipid Syndrome can be diagnosed and monitored.

If an Infectious Disease is suspected, it is advised to detect the serological status of the viral and/or bacterial antigen load in the patient sample. This new assay range will be used for Infectious Diseases like Infectious Mononucleosis caused by the Epstein-Barr Virus (EBV), Chicken Pox and Shingles (Herpes Zoster) caused by Varicella Zoster Virus (VZV) or for prenatal diagnostics (TORCH).

Jaap Stuut, CEO of IDS commented:

“We are delighted to have reached this agreement, and look forward to working with the team at TGS as we commercialise the IDS-iSYS Autoimmune and Infectious Disease assay portfolio. We now have access to a further 50 assays in additional territories which will complement our existing endocrinology portfolio and add to our competitive position as a result of the increased menu on the IDS-iSYS.

During the next financial year we will focus on obtaining regulatory approval outside Europe for these assays and on driving further commercialisation as soon as possible.”

For further information on any of our products, contact us by email at [email protected].